Japanese Patient Gets Stem-Cell Parkinson's Care

A Parkinson’s patient received pioneering stem-cell therapy at Kyoto University Hospital in October, marking the world’s first commercial application of the treatment following conditional regulatory approval in Japan.

Sumitomo Pharma developed the procedure, which transplants millions of induced pluripotent stem (iPS) cells into the patient’s brain.

Scientists derive these specialised cells from healthy donors and cultivate them into dopamine-producing precursors to replace damaged brain tissue.

Read More : Lagos Sets December 31 Health Insurance Deadline

Japanese regulators conditionally approved the therapy in March after successful clinical trials demonstrated both safety and symptomatic improvements across multiple trial participants.

Japan patient gets stem-cell Parkinson's care (News Central TV) — A Japanese patient gets stem-cell Parkinson’s care. Credit: NPR

Sumitomo Pharma announced plans to treat 20 to 30 additional patients by March 2029 while simultaneously conducting clinical trials in the United States.

Full regulatory approval in Japan hinges on confirming safety and efficacy data gathered over the next seven years.

Author

Abisoye Adeyiga

Abisoye Adedoyin Adeyiga holds a PhD in Languages and Media Studies and a Master’s in Education (English Language). Trained in digital marketing and investigative journalism, she is passionate about new media’s transformative power. She enjoys reading, traveling, and meaningful conversations.